Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 6 Colorectal Neoplasms 3 Solid Tumors 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Gastrointestinal Neoplasms 1 Disease Progression 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced Solid Tumors 1

Interventions

Sorafenib 79 pembrolizumab 37 Bevacizumab 36 Nivolumab 33 lenvatinib 30 atezolizumab 24 durvalumab 17 Oxaliplatin 12 Ipilimumab 12 regorafenib 9 Capecitabine 9 tremelimumab 8 Injections 8 Doxorubicin 8 tislelizumab 7 sintilimab 7 Fluorouracil 7 cabozantinib 6 budigalimab 6 brivanib 6 Ramucirumab 6 toripalimab 5 Gemcitabine 5 Everolimus 5 Cyclophosphamide 5 ADI PEG20 5 fludarabine 4 Sunitinib 4 Leucovorin 4 E-7386 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma, Hepatocellular × tivozanib × Clear all

NCT03970616 2023-07-12

DEDUCTIVE

AVEO Pharmaceuticals, Inc.

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡